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ORIGINAL ARTICLE
Melatonin rhythms in renal transplant recipients with sleep–wake disturbances
Hanna Burkhaltera,b, Sabina De Geestb,c, Anna Wirz-Justiced, and Christian Cajochend
aCentre for Sleep Medicine, Hirslanden Group, Zürich, Switzerland; bInstitute of Nursing Science, University of Basel, Basel, Switzerland;
cAcademic Center for Nursing and Midwifery, KU Leuven, Belgium; dCentre for Chronobiology, Psychiatric Hospital of the University of Basel,
Basel, Switzerland
ABSTRACT
We assessed salivary melatonin levels in renal transplant (RTx) recipients who participated in a
randomised, multicentre wait-list controlled trial on the effect of bright light therapy on their
sleep and circadian rhythms. A large proportion of RTx recipients in our cohort had unexpectedly
low melatonin values, which precluded calculation of the dim-light melatonin onset (DLMO) as a
circadian marker. Thus, the aim of this post hoc analysis was to describe the melatonin profile of
home-dwelling RTx recipients diagnosed with sleep–wake disturbances (SWDs). The participants
were characterised by means of sleep questionnaires, validated psychometric instruments
[Pittsburgh sleep quality Index (PSQI), Epworth sleepiness scale (ESS), Morningness-Eveningness
Questionnaire (MEQ) and Depression, Anxiety and Stress Scale (DASS)] in addition to melatonin
assay in saliva. Data were analysed with descriptive statistics and group comparisons made with
appropriate post hoc tests. RTx recipients [n = 29 (aged 54.83 ± 13.73, transplanted 10.62 ± 6.84
years ago)] were retrospectively grouped into two groups: RTx recipients whose dim light
melatonin onset (DLMO) could be calculated (n = 11) and those whose DLMO could not be
calculated (n = 18). RTx recipients having a measurable DLMO had a number of differences from
those without DLMO: they were younger [46.4 ± 14.9 compared to 60.0 ± 10.3 (p = .007)], had
higher haemoglobin values [135.36 ± 12.01 versus 122.82 ± 11.56 (p = .01)], less anxiety [4 (0;8)
versus 12 (6.5;14) (p = .021)] and a better overall sense of coherence [SOC Score: 71.09 ± 12.78
versus 56.28 ± 15.48 (p = 0.013)]. These results suggest that RTx recipients whose DLMO could be
calculated have less health impairments, underlying the relevance of a stable circadian system.
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Introduction
The purpose of the main study was to evaluate the
feasibility of implementing a daily morning bright
light therapy intervention in renal transplant
(RTx) recipients with sleep disturbances, in the
community setting, and to conduct a preliminary
exploration of its efficacy for improving sleep
characteristics (Burkhalter et al., 2015).
The sleep–wake cycle is one of many circadian
rhythms driven by the biological clock located in
the suprachiasmatic nuclei and synchronised to the
24-hour day by daylight (Vitaterna et al., 2001).
Sleep–wake disturbances (SWDs) are actual or
perceived changes in sleep resulting in daytime
impairment. Poor sleep quality (30.7%) and poor
daytime functioning (34.1%) affect many RTx
patients (Burkhalter et al., 2011). In the general
population, poor sleep is positively associated with
obesity (Cappuccio et al., 2008), heart disease
(Cappuccio et al., 2011), type 2 diabetes (Cappuccio
et al., 2010) and depression (Alvaro et al., 2013). RTx
recipients are already at risk for these factors [cancer
(Wong & Chapman, 2008); coronary heart disease
(Israni et al., 2010), diabetes, dyslipidemia, hyperten-
sion (Lodhi et al., 2011), depression (Rosenberger
et al., 2005)] due to lifelong immunosuppressive
therapy and fear of acute or chronic rejection
(Lodhi et al., 2011) .
Endogenous melatonin levels are normally low
during the day, increase in the evening, peak in the
middle of the night and gradually fall during the
second half of the night (Nagtegaal et al., 1998).
The increase in melatonin secretion in the evening
correlates with an increase in sleep propensity
(Uchiyama et al., 2002). Thus, the endogenous
melatonin rhythm exhibits a close association
with the endogenous circadian component of the
sleep propensity rhythm. This has led to the idea
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that melatonin is an internal sleep “facilitator” in
humans (Cajochen et al., 2003). Melatonin is also a
key factor initiating a thermoregulatory cascade
which decreases heat production and induces
vasodilatation of distal skin regions leading to
heat loss, which in turn increases sleepiness and
decreases core body temperature preparatory for
sleep (Kräuchi et al., 2006). The evening melatonin
rise represents an established marker for circadian
phase in clinical settings when the entire nocturnal
rhythm cannot be measured. Thus, the dim-light
melatonin onset (DLMO) is a standardised
estimate of circadian phase when samples are
collected under dim light conditions to avoid
suppression of synthesis (Lewy & Sack, 1989).
Saliva for melatonin assay is often self-collected
and stored at home with reliable results (Keijzer
et al., 2011). Measurement interference can arise
from bleeding gums (Pullman et al., 2012), tooth-
paste (Figueiro & Rea, 2010), caffeine, tobacco and
alcohol (Hartter et al., 2006; Zhou et al., 2009)
leading to erratic values. Further, benzodiazepines
(Hajak et al., 1996; McIntyre et al., 1988; McIntyre
et al., 1993), beta blockers (Scheer et al., 2012;
Stoschitzky et al., 1999; Vijayasarathy et al.,
2010), nonsteroidal anti-inflammatory drugs
(Murphy et al., 1996), anticoagulants (Zhou et al.,
2009), diabetes medications (Nagorny & Lyssenko,
2012) and oral contraceptives (Hilli et al., 2008)
have been associated with low melatonin values.
Melatonin secretion declines with age (Sack et al.,
1986) and growth (Bojkowski & Arendt, 1990;
Griefahn et al., 2003). People with hormone cycle
dysfunction, damaged melatonin receptors (fragile X
syndrome), disease-induced night–day rhythm
reversal (e.g. Smith-Magenis Syndrome, a develop-
mental disorder), or calcification of the pineal gland
(Kunz et al., 1999; Mahlberg et al., 2009) require up
to 100% melatonin supplementation (Van Thillo
et al., 2010). People with a melatonin deficiency or
disruption have an increased prevalence of sleep
disorders (Haimov et al., 1994) and sleep–wake
cycle disturbances (Pandi-Perumal et al., 2005).
However, patients after pinealectomy did not have
major sleep disturbances (Macchi & Bruce, 2004).
Thus, normal daily melatonin profiles may contri-
bute to sleep problems but not necessarily determine
them, and their functional significance is unclear
(Macchi & Bruce, 2004).
Based on the overview of possible mechanisms
of desynchronisation of sleep–wake rhythms,
leading to sleep disturbances in dialysis patients
(Parker, 2003) and in patients with chronic kid-
ney disease (Russcher et al., 2012), we assume
similar mechanisms for RTx recipients. The only
significant finding in the intervention group after
bright light therapy, applied each morning to
regularise nocturnal sleep, was a phase advance
in both get-up time and bedtime in the actimetry
data (Burkhalter et al., 2015). However, only very
few participants had a measureable DLMO, which
precluded documenting any parallel advance in
DLMO after morning light therapy. We therefore
performed a post hoc analysis of the baseline
database of saliva melatonin profiles to elucidate
any clinical differences between RTx recipients
with and without a DLMO. The aim of this
study was to descriptively explore relevant
variables associated with low respectively no
melatonin secretors for future melatonin analysis
in RTx recipients and in other chronic diseases.
Material and methods
This descriptive analysis was based on the baseline
data of a multicentre randomised wait-list con-
trolled design study (Burkhalter et al., 2015). The
intervention group completed 3 weeks of baseline
measurement, followed by 3 weeks of morning
bright light therapy, then a 3-week post-treatment
assessment. The baseline assessment for the con-
trol group had a 9-week duration, followed by 3
weeks of morning bright light therapy.
Participants, eligibility criteria and setting
Participants were recruited at the University
Hospitals of Basel, Berne and Zurich and had all
participated in a screening study to evaluate sleep
disorders in these patients (Burkhalter et al., 2013;
Burkhalter et al., 2014). The inclusion criteria were
adult RTx recipients more than 1 year post-trans-
plant and diagnosed with SWD (sleep assessment
interview in the preceding study); German speak-
ing; on stable immunosuppressive drugs and no
signs of acute rejection. Thirty were recruited; one
dropped out. Baseline conditions were the same
for the intervention and the control groups.
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Measures
Clinical characteristics
Clinical characteristics [age in years, gender,
years since transplantation, BMI (kg/m2), blood
creatinine, haemoglobin, blood urea nitrogen and
the Charlson Comorbidity Index] were retrieved
from the participants’ hospital medical charts.
Sleep quality (Pittsburgh Sleep Quality Index:
PSQI), daytime sleepiness (Epworth Sleepiness
Scale: ESS), depression, anxiety and stress sympto-
matology (Depression, Anxiety and Stress Scale:
DASS-21), seasonal depression (Personal Inventory
for Depression and Seasonal Affective Disorder:
PIDS-SA), sense of coherence (Sense of Coherence:
SOC-13 (Antonovsky, 1993)), physical activity
(Godin Leisure-Time Exercise Questionnaire:
GLTEQ (Godin & Shephard, 1985)), chronotype
(Morningness-Eveningness Questionnaire) and the
sleep measurements (assessment questionnaire)
were retrieved from our previous observational
study data bank (Burkhalter et al., 2011; Burkhalter
et al., 2013; Burkhalter et al., 2014). A high sense of
coherence reflects an attitude of confidence that life
events (e.g. pain, illness, sleep disturbance. . .) (1) are
structured, predictable and explicable; (2) the
resources are available to one to respond to
this life event and (3) and that this situation is a
challenge that is worth investment and engagement
(Antonovsky, 1993).
Melatonin profiles
To determine melatonin values, participants col-
lected saliva samples using Salivettes (Sarstedt AG,
Sevelen, Switzerland) and were asked to do this
under dim home lighting conditions. They collected
saliva on day 1 of baseline, the final day of BLT and
the final day of the study. For each 24-h collection
period, participants collected and refrigerated up to
five samples at 1-h intervals, starting 5 h before
predicted bedtime and ending at bedtime, as well as
night-time samples should they wake up, and then a
series after wake time and 3 during the day.
Melatonin was measured via direct double-antibody
radioimmunoassay (analytical sensitivity: 0.2 pg/ml)
and a functional minimum detectable dose of 0.65
pg/ml (Bühlmann Laboratories AG, Allschwil,
Switzerland)(Weber et al., 1997). Salivary melatonin
is normally below 3 pg/ml during the daytime and
up to 10 pg/ml at bedtime (Altpeter et al., 2006), with
broad individual variability in maximum secretion
(peak values: 2–84 pg/ml) (Burgess & Fogg, 2008).
To determine a DLMO at least five salivary melato-
nin measures are needed and at least one sample has
to show a significant concentration elevation com-
pared to daytime samples. The DLMOwas estimated
by an objective “hockey stick” method developed for
sensitivity and reliability (Danilenko et al., 2014).
The phase angle describes the relationship
between the timing of the biological clock and
the timing of external cues (Emens et al., 2009).
The phase angle between the DLMO and sleep
onset time was calculated by subtracting the
DLMO time from the patient’s bedtime.
Data collection
The current study was approved by the relevant
ethics committees of Basel, Bern and Zurich. Data
were collected from December 2010 until
September 2012 and details are described in the
main study (Burkhalter et al., 2015).
Statistical analysis
We used descriptive statistics including means,
standard deviations (SDs), medians, quartiles, fre-
quencies, cross-tabulations and graphs to uncover
any data anomalies, such as missing values, out-
liers or extreme values, as well as the variables
under study to determine their levels of measure-
ment and data distributions. The Mann–Whitney
U test and Phi tests (for nominal or dichotomous
variables) and independent t-tests were used to
explore differences between groups. The level of
significance was set at p < 0.05. SPSS 22 Statistics
software (Version 22.0.0, IBM Corporation,
Armonk, New York, United States) was used for
statistical analysis.
Results
Almost two-thirds of the patients had extremely
low or unmeasurable melatonin levels. Thus, RTx
recipients [n = 29 (aged 54.8 ± 13.7, transplanted
10.6 ± 6.8 years ago)] were separated retrospectively
into two groups: RTx recipients whose DLMO
could be calculated (n = 11) and those whose
812 H. BURKHALTER ET AL.
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DLMO could not (n = 18). Table 1 shows the
sample characteristics of the two groups. Figure 1
shows the saliva melatonin profile over night. The
mean DLMO was similar to a healthy population:
21.7 h ± 0.95 versus 20.1 ± 1.1 (morning types) and
21.7 h ± 0.95 versus 22.0 ± 1.2 (evening types)
(Emens et al., 2009), but the phase angle of
DLMO to bedtime was shorter than in this healthy
population: 1.2 ± 1.5 hversus 2.2 ± 1.1 (morning
types) and 1.2 ± 1.5 hversus 1.6 ± 1.1(evening types)
(Emens et al., 2009; Lewy et al., 2006).
RTx recipients having a measurable DLMO had a
number of differences from those without DLMO:
they were younger [46.4 ± 14.90 compared to 60.0 ±
10.3 (p = .007)], had higher haemoglobin values
[135.36 ± 12.01 versus 122.82 ± 11.56 (p = .01)],
less anxiety [4 (0;8) versus 12 (6.5;14) (p = .021)]
and a better overall sense of coherence [(SOC score
71.09 ± 12.78 versus 56.28 ± 15.48 (p = .013)]. There
were also tendencies to lower BMI [23.21 ± 4.06
versus 27.14 ± 5.58 (p = 0.053)], to have better
blood urea nitrogen values [6.36 ± 1.23 versus
8.49 ± 3.51 (p = 0.064)], less stress [8 (4;16) versus
15 (9;30) p = 0.076], better subjective sleep efficiency
[(PSQI 77.0 ± 16.37 versus 61.55 ± 24.81 (p = .078)],
fewer sleep interruptions [2 (2;3) versus 3 (2;3.25)
p = 0.084], less difficulty waking up [22% versus 54%
(p = 0.076)], be less tired [2 (1;3) versus 3 (2;4)
p = 0.092] and demonstrate higher comprehensibil-
ity (a belief that life events are happening because of
a reason) [SOC Comprehensibility score: 26.55 ±
5.85 versus 22.56 ± 5.91 (p = 0.088)]. However,
fewer had a kidney from a living donor [18% versus
44% p = 0.093].
Further descriptive differences (n.s.) between
RTx recipients with and without DLMO were: less
sleep medication (9.1% versus 33.3%), fewer beta
blockers (27.3% versus 44.4%), half had 100%
employment (54.4% versus 27.7%) and they showed
a lower chance to doze off during the day (9.1%
versus 22.2%). The perceived sleep latency was
shorter (27.45 min versus 55.17 min) and the sleep
duration as well (5.29 h versus 5.94 h).
Figure 1 shows that the DLMO group had fewer
nocturnal wake-up saliva samples (n.s.). It is also
clear from the figure that the individuals without
DLMO also had low melatonin throughout the
night, whereas the DLMO group also showed the
characteristic morning decline after waking.
Discussion
To our knowledge, this is the first study describing
saliva melatonin profiles in RTx recipients with
SWDs. Our results suggest that RTx recipients
whose DLMO could be calculated have less health
impairments, underlying the relevance of a stable
circadian system.Melatonin amplitude andmelatonin
rhythm have been shown to decrease in chronic kid-
ney disease patients with advancing renal dysfunction
(Koch et al., 2010). There is only one study of 23 RTx
recipients with salivamelatoninmeasurements at pre-
Tx and 3 months post-Tx (Russcher et al., 2015).
Although melatonin values were low in this study,
theDLMOwas always calculable. Themain difference
to our study was that we only included patients with
poor sleep quality and daytime sleepiness, while
Russcher et al. also included patients with good sleep
quality and no daytime sleepiness.
Low saliva melatonin values
Since we had 2–4 melatonin evening profiles for
each patient throughout the study (data not
shown), the presence of consistently low values or
consistently normal values provided reliability, i.e.
that these were not an artefact of non-adherence to
the study (e.g. toothpaste, using electronic devices
that emit melatonin-suppressing blue light). There
is now a long tradition of studying home-collected
melatonin samples with good reliability; we can
therefore assume that our participants correctly
collected saliva samples.
Low saliva melatonin values in RTx recipients
might arise from different causes. First of all, there
was a 13.6-year age difference between the groups,
and it is known that melatonin secretion declines
with age (Pandi-Perumal et al., 2005). However, our
analysis with respect to age did not explain the
relevant melatonin differences between the groups
(significant for younger age were the expected vari-
ables such as taking fewer beta blockers, later
DLMO, working 100%, suffering sleep difficulties,
more impairment following sleep problems, more
difficulty to wake up and lower sense of coherence).
In daytime haemodialysis patients an absence
(Karasek et al., 2005) in the nocturnal rise in
melatonin concentration has been reported (Koch
et al., 2009) probably due to the dialysis itself. Very
CHRONOBIOLOGY INTERNATIONAL 813
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Table 1. Demographics, clinical data, psychosocial and sleep characteristics of 29 renal transplant recipients with sleep disorders.
N = 11 (DLMO)
N = 29 Mean ± SD N = 18 (no DLMO)
DLMO (decimal time) 21.7 ± 0.95
Phase angle DLMO to bedtime (h) 1.2 ± 1.5
Demographics Per cent Per cent Per cent Phi/Kruskall/T p Value
Mena 51.7 54.5 50.0 0.044 0.812
Mean ± SD Mean ± SD Mean ± SD T-test p Value
Age (years)a 54.8 ± 13.7 46.4 ± 14.9 60.0 ± 10.3 −2.924 0.007
BMIa 25.6 ± 5.3 23.2 ± 4.1 27.1 ± 5.6 −2.026 0.053
100% workc 37.9 54.5 27.7 0.268 0.149
Clinical Median Median Median Mann–Whitney U test
Charlson Comorbidity Indexa 1 (0;2) 2 (0;2) 1(0;2) 0.746
Mean Mean Mean T-test p Value
Years since RTxa 10.6 ± 6.8 11.2 ± 8.1 10.3 ± 6.2 0.34 0.737
Creatinine (µmol/l) a 115.5 ± 47.4 106.8 ± 34.6 121.1 ± 54.3 −0.771 0.448
Haemoglobin (g/l) a 127.7 ± 13.1 135.4 ± 12.0 122.8 ± 11.6 2.761 0.01
Blood Urea Nitrogen (mmol/l) a 7.7 ± 3.00 6.4 ± 1.2 8.5 ± 3.5 −1.933 0.064
Per cent Per cent Per cent Phi/Kruskall/T p Value
Taking beta blockera 37.9 27.3 44.4 0.172 0.355
Taking sleep medicationsc 24.1 9.1 33.3 0.275 0.139
Had a living graft donora 34.5 18.2 44.4 0.324 0.093
Sleep Mean ± SD Mean ± SD Mean ± SD T-test p Value
Sleep quality (PSQI Score) b 12.2 ± 3.6 10.9 ± 3.7 12.9 ± 3.4 −1.508 0.143
Sleep efficiency (%)b 67.4 ± 23.0 77.0 ± 16.4 61.5 ± 24.8 1.83 0.078
Sleep latency (min)c 44.7 ± 52.9 27.4 ± 19.0 55.1 ± 63.9 −1.392 0.175
Median Median Median Mann–Whitney U test
Sleep interruptionsc 2 (1;3) 1 (1;3) 3 (2;3.25) 0.084
Tirednessc 3 (2;4) 2 (1;3) 3 (2;4) 0.092
Mean Mean Mean T-test p Value
Sleep latency after interruption (min) c 31.1 ± 42.6 36.4 ± 52.0 27.8 ± 36.9 0.517 0.609
Sleep duration (h) c 5.7 ± 1.7 5.3 ± 1.5 5.9 ± 1.8 −0.989 0.332
Daytime Mean ± SD Mean ± SD Mean ± SD T-test p Value
Daytime sleepiness (ESS Score)b 7.7 ± 3.7 7.2 ± 3.7 8.1 ± 3.8 −0.605 0.55
Per cent Per cent Per cent Phi/Kruskall/T p Value
Have difficulties to wake upc 34.5 54.5 22.2 0.33 0.076
High chance to doze offc 17.2 9.1 22.2 0.64 0.732
Have impaired daytime functioningc 48.3 45.5 50 0.44 0.812
Psychosocial Mean ± SD Mean ± SD Mean ± SD T-test p Value
SOC Scoreb 61.9 ± 16.0 71.1 ± 12.8 56.3 ± 15.5 2.663 0.013
SOC Comprehensibilityb 24.1 ± 6.1 26.5 ± 5.8 22.6 ± 5.9 1.77 0.088
SOC Manageabilityb 17.2 ± 4.9 19.1 ± 4.5 16.1 ± 5.1 1.611 0.119
SOC Meaningfulnessb 18.8 ± 5.4 20.6 ± 4.2 17.6 ± 5.9 1.491 0.148
MEQ Scoreb 55.8 ± 10.8 53.9 ± 12.5 56.9 ± 9.8 −0.729 0.472
GLTEC Scoreb 38.3 ± 24.4 42.4 ± 19.9 35.8 ± 27.0 0.693 0.494
Median Median Median Mann–Whitney U test
DASSDb 10 (2;20) 4 (2;14) 16 (2;24.5) 0.159
DASSAb 8 (2;13) 4 (0;8) 12 (6.5;14) 0.021
DASSSb 14 (6;18) 8 (4;16) 15 (9;30) 0.076
PIDS Scoreb 3 (1.5;5) 3 (0;3) 3.5 (1.75;6) 0.188
SAD Scoreb 7 (3;9.5) 5 (1;8) 7 (3.75;10.5) 0.276
aMedical charts; bSurvey study 1; cSleep questionnaire study 2.
SD = standard deviation; DLMO = dim-light melatonin onset; PSQI = Pittsburgh Sleep Quality Index; ESS = Epworth Sleepiness Scale; SOC = Sense of
Coherence; GLTEC = Godin Leisure-Time Exercise Questionnaire; MEQ = Morningness-Eveningness Questionnaire; DASS = Depression Anxiety and
Stress Scale; PIDS = Personal Inventory for Depression; SAD = Seasonal Affective Disorder Questionnaire.
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low values were also found (Koch et al., 2010) in
chronic kidney failure patients significantly corre-
lating with failure degree (Koch et al., 2010). Our
sample however was stable with regard to kidney
function (we excluded patients with acute rejection
or hospitalisation) and had good renal function.
Eleven of the participants were taking beta
blockers, which may diminish melatonin synthesis
(Stoschitzky et al., 2006). However, 3 out of 11
patients taking beta blockers were in the DLMO
group. Thus, since only 8 of the 18 patients with
non-calculable DLMO took beta blockers; this
may not be the main reason for the observed low
melatonin values in the no-DLMO group. This
corroborates findings in haemodialysis patients
(Koch et al., 2009) where beta blockers did also
not explain low melatonin values. Another reason
for low melatonin could relate to the calcification
of the pineal gland (Kunz et al., 1999), since a
characteristic of chronic kidney disease is high
vascular calcification. Multiple risk factors, such
as high calcium and phosphorus burden, abnormal
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Figure 1. Saliva melatonin profile among (a) RTx recipients with a DLMO and (b) RTx recipients without a DLMO . In brackets at each
time point are the actual number of individuals. The sleep period was between bedtime and get-up. The usual cut-off for DLMO with
this assay is 3 pg/ml. Wake-up measures represent saliva samples taken during nocturnal awakenings. Plots are median and
interquartile range.
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bone metabolism, impaired renal excretion and
medication, induce vascular smooth muscle cells
to change into chondrocyte or osteoblast-like cells
(Moe & Chen, 2008).
Further, the DLMO group had a prior health
disadvantage: Table 1 shows that fewer patients in
the DLMO group had a kidney from a living
donor, yielding a worse health condition pre-Tx
(Pippias et al., 2015). Longer pre-transplant dialy-
sis duration is associated with poorer outcome in
kidney-transplanted patients (Remport et al.,
2011). If a partner, parents or friends are willing
to donate a kidney, the patient in need can plan
the transplantation early in the disease course and
might avoid haemodialysis. Pre-emptive transplan-
tation (avoiding haemodialysis) is associated with
higher patient survival and improved quality of life
(Jay et al., 2015).
Is low melatonin an indicator for worse health?
Besides haemodialysis patients, we are not aware of
any patient group that has such a high percentage of
low or no melatonin secretors. It may be related to
the transplantation itself, or to the long-term treat-
ment following transplantation (e.g. side effects of
immunosuppressants and oxidative stress). RTx
recipients whose DLMO was uncalculable were
older, but not more ill in view of comorbidities
(e.g. the Charlson Comorbidity Index was even
lower in this group). However, in view of health,
this group had lower haemoglobin that could be
associated with iron deficiency and anaemia. Lower
haemoglobin values are not associated with older age
(Hawkinset al., 1954). Anaemia is a risk factor for
cardiovascular complication in RTx recipients (Mix
et al., 2003). They had higher urea values (showing a
decrease of kidney function) further, they had a
higher BMI that is a risk factor for cardiovascular
diseases. This group also had fewer resources to cope
and fewer resources effective in avoiding or combat-
ing a range of psychosocial stressors. This is shown
in the lower sense of coherence score (the lower the
score, the fewer available coping resources to face
life-stress experience) and in the higher scores of
anxiety and stress symptomatology.
The fewer nocturnal wake-up saliva samples in the
DLMO group suggest a sounder sleep (Figure 1).
Additionally, the characteristic morning decline after
waking in the DLMO group is another confirmation
of a sound circadian rhythm in this patient group.
Patients having an SWD and showing no DLMOmay
be at a higher risk for other illnesses (Hardeland et al.,
2012). For these reasons we suggest that RTx recipi-
ents who have measurable melatonin rhythms may
suffer less health impairment, thus supporting the
relevance of a stable circadian system.
Clinical relevance
The meaurement of salivary DLMO cannot be per-
formed routinely in RTx recipients, neither would this
be recommended. Instead, routine assessment of self-
reported sleep quality and daytime sleepiness should
be performed regularly with a simple visual analogue
scale (Burkhalter et al., 2011). The detection of poor
sleep quality and/or excessive daytime sleepiness
should prompt a sleep assessment (Burkhalter et al.,
2013) with a sleep diary or an actimeter (objective
data). Thereafter, sleep hygiene rules should be
encouraged, including regular sleep–wake schedules,
exposure to bright light in the early hours of the
morning (e.g. a 30-minute walk outdoors) and avoid-
ance of bright light exposure (particularly the blue
screens of electronic devices) in the evening
(Stepanski &Wyatt, 2003). If there is no improvement
with these behavioural interventions, a diagnostic
clarification could help through measurement of sali-
vary DLMO (Bühlmann Laboratories AG, Allschwil,
Switzerland – www.buhlmannlabs.ch).
Therefore, instead of prescribing sleeping pills, it
might be useful to first try melatonin supplementa-
tion for those without melatonin secretion in the
evening. Melatonin supplementation (3 mg) at
22:00 pm has shown good results in haemodialysis
patients. Melatonin supplementation recovered the
low nocturnal melatonin rise of these patients and
improved sleep fragmentation, sleep onset latency
and subjective sleep quality (Koch et al., 2009). All
efforts targeting a high nocturnal melatonin and
intact melatonin signalling are in favour of avoiding
various illnesses (Hardeland, 2012) and keeping a
well-synchronised sleep–wake cycle.
Melatonin deficiency has been associated with
prostate, endometrial and breast cancer (Hardeland,
2012). RTx recipients are at 2.5- to 3.9-fold higher
risk for cancer compared to genral population
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(Janus et al., 2012). This is therefore an additional
reason to measure salivary DLMO.
Melatonin induces beneficial effects at numerous
pathophysiological levels related to chronic kidney
disease both under experimental (Quiroz et al.,
2008) and clinical conditions (Hrenak et al., 2015).
It has been suggested that melatonin supplementa-
tion is beneficial in neurodegenerative disorders, by
protecting brain cells from oxidative stress (Miller
et al., 2015). These results are promising in view
that transplanted kidneys are prone to oxidative
stress-mediated injury by pre-transplant and post-
transplant conditions that cause reperfusion injury
or imbalance between oxidants and antioxidants
(Nafar et al., 2011). An animal study has even
proposed to supplement patients taking tacrolimus
(one of the most often used immunosuppressive
drugs in RTx recipients) with melatonin. Further
clinical and experimental studies are needed, as the
administration of melatonin might protect the
livers of tacrolimus-treated patients by reducing
the severity of oxidative stress and increasing the
levels of antioxidant enzymes (Karabulut & Ara,
2009).
Conclusion
Assessing and treating SWDs in RTx recipients
could be relevant for improving clinical outcome.
This study originally investigated 926 RTx recipi-
ents (Burkhalter et al., 2014), of whom 21.3%
reported daytime sleepiness (ESS > 10) and 58.6%
reported poor sleep quality (PSQI > 5); 249 RTx
recipients participated in a sleep survey and 164
RTx participated in the subsequent sleep assess-
ment to determine a preliminary sleep disorders
diagnosis (Burkhalter et al., 2013); 49 had a putative
diagnosis of SWD, of whom 30 participated in the
bright light intervention study (Burkhalter et al.,
2015). Within this latter group a high majority
had low or no melatonin rhythm. These results
suggest that RTx recipients without melatonin
rhythms have more health impairments.
Strengths and limitations
Strengths of this study included our use of salivary
melatonin samples to objectively estimate circadian
rhythms with the DLMO. Here we found highly
reproducible individual melatonin data when
comparing 2–4 profiles. In addition to the melato-
nin curves, many self-reported questionnaires and
clinical data gave a broad insight into this
population.
Limitations of this study were the post hoc
nature of the analysis. The study was not designed
based on a theoretical framework. This led to a
conservative analysis, focussing on descriptive
results. We performed additional statistical tests
to minimise Type I Error and to detect whether
significant correlations could be explained by the
age difference of the two groups, which it did not.
Future full-powered studies sould be aware of the
statistical limitation we had with such a small
sample size. An additional limitation was that
our study assessed drugs by groups and not sub-
stance classes (e.g. we had a category beta blockers
but did not distinguish between beta 1-selective
blockers (atenolol, bisoprolol), non-selective beta
blocker (propranolol) and vasodilatator beta
blockers (carvedilol and nebivolol). Therefore, the
three RTx recipients who had a DLMO might have
been taking carvedilol or nedivolol which does not
suppress melatonin (Scheer et al., 2012; Wyatt
et al., 2006).
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